Skip to main content

Table 4 Distribution of adverse events in the studies

From: A systematic review of the efficacy of a single dose artemisinin–naphthoquine in treating uncomplicated malaria

Study author, publication year [reference]

Sample size (ASNQ/comparator)

Comparator drug

Study country

ASNQ group

Comparator group

Hombhanje et al., 2009 [19]

51/49

CQ-SP

PNG

Transient deafness: 7.8 %

Transient deafness: 2 %

Itchiness: 2 %

Itchiness: 4 %

Skin rash: 2 %

Skin rash: 2 %

Dark urine: 2 %

Dark urine: 0 %

Vomiting: 2 %

Vomiting: 4.1 %

Rujumba et al., 2010 [20]

113/112

AL

Uganda

NA

NA

Kinde-Gazard et al., 2012 [21]

84/90

AL

Benin

Nausea: 9.5 %

Nausea: 7.8 %

Itchiness: 2.3 %

Itchiness: 2.2 %

Abdominal: pain: 6.3 %

Abdominal: pain: 5.5 %

Tjitra et al., 2012 [22]

201/200

DHP

Indonesia

Nausea: 57 %

Nausea: 54 %

Headache: 55 %

Headache: 55 %

Udoh et al., 2014 [23]

43/54

AL

Nigeria

Transient maculopapular rash: 0.23 %

None

  1. AL arthemether-lumefantrine (Coartem), ASNQ artemisinin–naphthoquine single dose, CQ chloroquine, DHP dihydroartemisinin–piperaquine, SP sulphadoxine-pyrimethine, NA not available/not mention